Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase-δ (PI3K-δ) and PI3K-γ in late-stage clinical development for hematologic malignancy treatment. This phase 1 study evaluated maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib in 210...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Flinn, Ian W., O’Brien, Susan, Kahl, Brad, Patel, Manish, Oki, Yasuhiro, Foss, Francine F., Porcu, Pierluigi, Jones, Jeffrey, Burger, Jan A., Jain, Nitin, Kelly, Virginia M., Allen, Kerstin, Douglas, Mark, Sweeney, Jennifer, Kelly, Patrick, Horwitz, Steven
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033052/
https://ncbi.nlm.nih.gov/pubmed/29191916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-786566
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados